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cell	 loss	 in	neurodegenerative	diseases,	 including	glaucoma	and	Alzheimer’s	disease,	 I	 investigated	
whether	the	quantification	of	dendritic	morphology	of	retinal	ganglion	cells	in	the	retinal	explant	could	
be	used	 as	 a	more	 sensitive	measure	of	 neuronal	 health	 after	 axotomy.	 I	 report	 here	 that	 retinal	
ganglion	cell	dendrite	loss	precedes	cell	loss	by	at	least	7	days	and	that	this	retraction	is	substantially	
retarded	 following	 treatment	 with	 brain-derived	 neurotrophic	 factor	 applied	 at	 the	 time	 of	
explantation.	Perhaps	most	importantly,	I	demonstrate	for	the	first	time	in	this	model	that	delayed	
application	of	brain-derived	neurotrophic	factor	significantly	protects	against	dendritic	retraction	of	
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Retinal	 ganglion	 cells	 (RGCs)	 are	 neurons	 in	 the	 inner	 retina	 that	 collect	 information	 from	




and	 RGCs	 are	 hyperpolarised	 by	 light.	 Following	 light	 transduction,	 photoreceptors	 synapse	 to	












Figure 1.1. Neural processing in the mammalian retina. Under scotopic conditions photoreceptors are 
depolarised and release glutamate, which hyperpolarised cone-driven ON bipolar cells and rod-driven 
bipolar cells via metabotropic glutamate receptors (Shiells and Falk 1990). Glutamate depolarises OFF 
bipolar cells via ionotropic glutamate receptors. Under photopic conditions glutamate release from 
photoreceptors is suppressed, resulting in depolarisation of ON bipolar cells and rod-driven bipolar cells, 
and hyperpolarisation of OFF bipolar cells (Stryer 1986). Cone-driven ON bipolar cells synapse to ON 
RGCs, and cone-driven OFF bipolar cells synapse to OFF RGCs. Bistratified RGCs receive signals 
from ON and OFF bipolar cells (Kolb 1970; Famiglietti and Kolb 1976; Nelson et al. 1978). Rod-driven 
bipolar cells synapse to AII amacrine cells, which in turn depolarise cone-driven ON bipolar cells via 
gap junctions, and hyperpolarise cone-driven OFF bipolar cells and OFF RGCs via glycine (Tagawa et 
al. 1999; Bloomfield and Dacheux 2001; Xu and Tian 2008). G (ganglion cell); A (amacrine cell); AII (AII 
amacrine cell); H (horizontal cell); B (bipolar cell); white cells in ONL (cones); black cells in ONL (rods); 
GCL (ganglion cell layer); IPL (inner plexiform layer); INL (inner nuclear layer); OPL (outer plexiform 
layer); ONL (outer nuclear layer); OS (outer segments). The IPL is divided into 5 strata (S1-S5); OFF 
cells (blue) stratify in S1-S2 (sublamina a); ON cells (red) stratify in S3-S5 (sublamina b); bistratified 

















Figure 1.2. Example types of mouse RGCs classified by soma diameter, dendritic field diameter and 
stratification depth, demonstrating the morphological variety of these neurons. Figure adapted from Sun 



















In	 general,	 neurons	 in	 the	 retina	 are	 formed	 from	 RPCs	 in	 descending	 size	 order,	 with	 the	
differentiation	of	RGCs	as	the	first	cell	type	(Jeffery	1997).	In	addition,	the	position	relative	to	the	optic	
nerve	seems	to	be	important;	RGCs	with	axons	deepest	in	the	optic	tract	are	formed	first	(alpha	cells	
in	rat,	beta	cells	 in	cat)	 (Reese	and	Colello	1992).	Low	sonic	hedgehog	(Shh)	concentrations	 induce	
expression	 of	 several	 genes,	 including	atonal,	 and	mitogen-activated	 kinase	 (MAPK)	waves,	which	






guidance	molecules	or	receptors	and	 intracellular	signal	molecules.	A	 list	of	 the	most	 important	of	
these	molecules	can	be	found	in	Table	1.1.
Table 1.1. Summary of molecules and proteins involved in the signalling cascades upstream of dendritic 
and axonal changes during development. 
	




























and	Ethell	2006).	Cadherin-integrin	 interaction	may	play	an	 integral	 role	 in	dendrite	development.	
Experiments	in	Drosophila	and	Xenopus	suggest	that	type	I	cadherins	and	β1	integrins	are	required	
for	dendrite	extension,	and	N-cadherin	inhibits	dendritic	branching	(Marrs	et	al.	2006).	
Semaphorins	 are	 a	 class	 of	 guidance	 cues	 that	 bind	 to	 their	 receptors	 neuropilins	 and	 plexins	
(Nakamura	et	al.	2000).	The	class	3	semaphorin	Sema3A	stimulates	dendrite	growth	and	branching	















synaptic	 remodelling	 has	 been	 observed	 in	 neurons	 in	 the	 hippocampus	 (Fischer	 et	 al.	 1998;	
Dunaevsky	et	al.	1999),	frontal	and	prefrontal	cortex	(Huttenlocher	1979;	Elston	et	al.	2009;	Petanjek	
et	al.	2011),	cat	visual	cortex	(Cragg	1975),	and	rabbit	auditory	cortex	(Rihn	and	Claiborne	1990).	In	
the	 developing	 retina	 glutamate	 signalling	 is	 important	 for	 the	 regulation	 of	 the	 final	 dendritic	
structure	and	synaptic	contacts	of	RGCs	(Bodnarenko	&	Chalupa	1993).	Glutamate	released	by	bipolar	
cells	 in	a	spontaneous	fashion	before	eye	opening	(Wong	1999)	and	as	a	result	of	 light	stimulation	
after	 eye	 opening	 causes	 increased	 calcium	 signalling	 following	 activation	 of	 the	 RGC	 glutamate	
receptors	(Xu	&	Tian	2007).	The	resultant	increased	stability	of	dendrites	and	synapses	may	be	due	to	















by	 neurons	 and	 glial	 cells	 and	 the	 net-like	 structure	 is	 laid	 down	 around	 the	 soma	 and	 proximal	
dendrites	of	neurons.	It	is	interesting	to	note	that	the	secretion	of	PNN	components	is	regulated	by	
neuronal	 activity;	 inhibition	 of	 sodium	 channels	 inhibits	 the	 formation	 of	 the	 PNN	 (Reimers	 et	 al.	
2007).	The	PNN	has	been	evidenced	to	play	important	roles	in	neuronal	protection,	by	acting	as	an	ion	
buffering	system,	as	well	as	the	modulation	of	synaptic	activity,	by	restricting	the	lateral	diffusion	of	











Levick	 1965;	 Torre	 and	 Poggio	 1978).	 RGC	 RFs	 and	 DFs	 are	 approximately	 equal	 in	 size,	 although	





et	 al.	 2000).	 In	 addition	 to	 spatial	 information,	 dendritic	 tiling	 of	 the	 retina	 permits	 maximum	
sensitivity	to	light,	and	means	that	there	is	little	redundancy	in	the	system	(Han	et	al.	2012).	
1.3.5	Cell	surface	antigens	































Retinal	 degeneration	 is	 one	 of	 the	 leading	 causes	 of	 blindness	 in	 the	world	 today	 (Quigley	 1996;	
Congdon	et	al.	2004;	Quigley	and	Broman	2006).	Age-related	macular	degeneration	(AMD)	commonly	
involves	the	deposition	of	drusen	and	degeneration	of	retinal	pigment	epithelium	(RPE),	 leading	to	











Retinitis	pigmentosa	 is	associated	with	degeneration	of	 the	photoreceptor	 layer	 (Dryja	et	al.	1990;	
Hartong	 et	 al.	 2006).	 RGCs	 are	 still	 present	 following	 photoreceptor	 death.	 However,	 it	 has	 been	
shown	that	transneuronal	degeneration	occurs	through	the	neuronal	pathway,	ultimately	resulting	in	
loss	 of	 RGCs	 (although	 this	 has	 been	 disputed	 in	 one	mouse	model),	 with	 evidence	 of	 abnormal	
electrical	 activity	 (Stone	 et	 al.	 1992;	 Strettoi	 et	 al.	 2002;	Mazzoni	 et	 al.	 2008;	 Stasheff	 2008).	 It	 is	
postulated,	 therefore,	 that	although	 introduction	of	photosensitive	 cells	or	 stimulation	of	 resident	
cells,	for	example	by	introduction	of	photosensitive	bacterial	proteins	via	gene	therapy	(Tomita	et	al.	










in	 Drosophila	 melanogaster	 undergoing	 morphogenesis	 (Kuo	 et	 al.	 2006;	 Williams	 et	 al.	 2006).	
Interestingly,	the	location	of	caspases	determines	the	downstream	effects;	local	caspase	activation	in	
dendrites	 causes	 dendritic	 pruning,	 whereas	 inhibition	 of	 the	 ubiquitin-proteasome	 machinery	
permits	global	caspase	activation	and	results	 in	cell	death	 	 (Rumpf	et	al.	2011;	Erturk	et	al.	2014).	
Other	 regulatory	 factors,	 such	 as	 reactive	 oxygen	 species	 or	 duration	 of	 caspase	 activation,	 may	
modulate	 the	downstream	effects,	 i.e.	 cell	death	or	dendritic	 remodelling	 (Snigdha	et	al.	2012).	 In	
addition,	it	has	been	demonstrated	in	mice	and	Drosophila	that	a	parallel	NAD+-dependent	pathway	
may	 regulate	 axonal	 pruning	of	 neurons	 during	 development	 (Schoenmann	et	 al.	 2010).	Although	
specific	details	are	yet	to	be	determined,	it	is	likely	that	the	process	of	dendritic	retraction	involves	




gliosis,	 which	 involves	 excessive	 glutamate	 signalling	 and	 activation	 of	 inflammatory	 pathways,	 it	
would	 be	 logical	 to	 predict	 that	 retinal	 degeneration	 could	 be	 associated	 with	 dendritic	 pruning.	































Yates	et	al.	2007).	 Increased	activity	of	 the	complement	pathway	aids	 in	breaking	down	apoptotic	
cells,	however	dysregulated	activity	may	contribute	to	tissue	degeneration.	
High	 ROS	 levels	 activate	 secretion	 of	 matrix	 metalloproteases	 (MMPs),	 which	 break	 down	 ECM	




their	 target.	 For	 these	 therapies	 it	 has	been	 found	 that	 integration	efficiency	 can	be	 increased	by	
manipulating	 ECM	 remodelling,	 for	 example	 by	 the	 addition	 of	 MMP-2,	 and	 compromising	 the	
integrity	of	the	OLM	(Zhang	et	al.	2007;	Barber	et	al.	2012).	
1.4.3	Neuroprotection	
RGC	death	 is	 the	 final	step	 in	most	cases	of	 retinal	degeneration,	and	since	they	are	the	cells	 that	
transmit	the	retinal	output	to	the	brain,	 if	this	step	can	be	prevented	some	visual	function	may	be	
preserved.	One	mechanism	contributing	to	RGC	apoptosis	in	glaucoma	is	postulated	to	be	blockage	of	
axonal	 retrograde	 transport	of	 growth	 factors	 to	 the	 soma	 (Quigley	1995),	which	may	 lead	 to	 cell	
stress.	Since	autophagy	 is	upregulated	by	oxidative	stress	and	excitotoxicity,	and	under	high	stress	
conditions	 may	 stimulate	 cell	 death,	 this	 may	 be	 implicated	 in	 glaucoma.	 On	 the	 other	 hand,	











sensitivity	 (Talcott	 et	 al.	 2011).	 Neuroprotection,	 in	 theory,	 should	 retard	 disease	 progression	 by	















(NGF),	BDNF,	neurotrophin-3	 (NT-3)	and	NT-4,	which	share	55%	sequence	 identity	 for	amino	acids	
(Suter	et	al.	1992)	and	most	have	low	affinity	for	the	p75	neurotrophin	receptor	(NTR).	Neurotrophins	
exert	 their	primary	downstream	effects	via	binding	to	tropomyosin	receptor	kinase	(Trk)	receptors	
(Table	 1.2).	Neurotrophins	 have	 essential	 roles	 during	 development	 and	 adult	 homeostasis	 of	 the	




Table 1.2. Summary of neurotrophins and their respective affinities for neurotrophin receptors 
(Dechant et al. 1997; Chao 2003). The relative affinities are important when considering interplay 























downstream	of	multiple	 cell	 signalling	 cascades.	 For	 example,	 transcripts	 that	 include	 exon	 IV	 are	













calcium	 stores	 via	 binding	of	 inositol	 1,4,5-trisphosphate	 to	 inositol	 1,4,5-trisphosphate	 receptors.	





Figure 1.3 Calcium response elements regulate transcription of bdnf exon IV in response to calcium. 
CaRE1 is bound by calcium responsive factor (CaRF) in response to calcium levels via signalling 
cascades including protein kinase A and PI3K. CaRE2 is bound by upstream stimulatory factor 1/2 
(USF1/2), a basic helix-loop-helix member. CaRE3 is bound by cAMP response element binding protein 
(CREB) in response to calcium levels via voltage-gated calcium channels and NMDA receptors. The 










bdnf	 (Martinowich	 et	 al.	 2003;	 Boulle	 et	 al.	 2012;	 Karpova	 2014).	 Downregulation	 of	 BDNF	 in	















may	be	mediated	 through	NGF	binding	 to	 p75NTR,	which	 facilitates	 binding	of	 the	 adapter	 protein	



































pro-neurotrophins	 and	 mature	 neurotrophins,	 which	 may	 be	 modulated	 through	 neurotrophin	




Figure 1.4 Summary of signalling cascades downstream of p75NTR and TrkB receptors via ligand 
binding. Pro-BDNF binds p75NTR and mature BDNF (mBDNF) binds TrkB. Pro-BDNF binding to p75NTR 
recruits sortilin and results in downstream JNK signalling, leading to cell death. Mature BDNF can bind 
to p75NTR and may inhibit downstream TrkB signalling through JNK and RhoA (not shown), or may 
strengthen BDNF binding to TrkB, increase MAPK and Akt signalling, and promote cell survival through 
NF-kB. Mature BDNF binds TrkB and stimulates downstream signalling of PLCγ, Akt and MAPK, 
leading to cell survival, neurite outgrowth, as well as increased BDNF transcription through upregulation 









associates	with	 p75	NTR	within	 the	 lipid	 raft,	 allowing	 γ-secretase	 to	 cleave	 the	 intracellular	 death	
domain	 of	 p75	 NTR	 and	 activate	 apoptosis	 signalling	 via	 stimulation	 of	 cytochrome	 c	 release	 from	
mitochondria.	In	the	presence	of	ligand	TrkA/C	dimerise,	permitting	recruitment	of	scaffold	proteins:	
Shc	recruitment	to	Tyr490	stimulates	the	Ras	pathway;	PLCγ	recruitment	to	Tyr785	stimulates	the	PKC	
















In	 common	with	 other	 secreted	 peptides,	 all	 neurotrophins	 are	 translated	 as	 a	 precursor,	 or	 pro-
neurotrophin.	 As	 outlined	 above,	 pro-neurotrophins	 and	mature	 neurotrophin	 signalling	 cascades	
have	 largely	 opposing	 effects,	 therefore	 the	 relative	 amounts	 of	 precursor	 versus	 processed	
neurotrophin	is	 likely	to	be	a	determining	factor	of	whether	the	end	result	 is	pro-apoptotic	or	pro-
survival.	 Since	 the	 ratio	 can	 be	 rapidly	 modulated	 by	 pro-neurotrophin	 processing,	 this	 enables	
neurotrophin	secretion	to	be	rapidly	switched	on	and	off	–	an	essential	property	of	molecules	that	




Mature	 neurotrophins	 are	 generated	 by	 proteolytic	 cleavage	 of	 the	 signal	 peptide	 on	 pro-




2008).	 In	non-neuronal	cells,	 such	as	astrocytes,	BDNF	 is	 sorted	 through	 the	constitutive	pathway.	
Neuronal	cells	use	both	 the	constitutive	pathway	and	the	regulated	pathway	 in	 the	golgi,	which	 is	
mediated	through	the	binding	of	sortilin	to	the	signal	peptide	of	pro-BDNF,	or	by	the	binding	of	CPE	
to	 a	motif	 on	 the	mature	 BDNF	 section	 of	 the	 protein.	 The	 constitutive	 pathway	 corresponds	 to	
constitutive	BDNF	release	and	the	regulated	pathway	corresponds	to	activity-dependent	secretion.	
The	precursor	and	mature	 forms	of	BDNF	are	 released	via	 secretory	vesicles	 into	 the	extracellular	
milieu,	where	pro-BDNF	can	be	processed	by	plasmin	(a	serine	protease;	Figure	1.5)	or	by	MMP-3	and	
MMP-7	(Lee	et	al.	2001;	Pang	et	al.	2004;	Dwivedi	2012).	Plasmin	is	 inhibited	by	the	blood-derived	
protein	 α-2-macroglobulin,	 which	 may	 reduce	 BDNF	 processing	 as	 well	 as	 directly	 blocking	 TrkB	
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phosphorylation	 in	 dopaminergic	 neurons	 (Hu	 and	 Koo	 1998).	 Processing	 may	 be	 particularly	





Figure 1.5 Extracellular BDNF processing. Extracellular pro-BDNF is cleaved at Arg-125-Val by 






formation	and	 stabilisation	of	 synapses	 through	 transcriptional	 changes	associated	with	 long-term	
potentiation	(LTP)	and	dendritic	spine	growth,	in	part	through	regulation	of	the	translation	of	Homer2,	
a	scaffold	protein	implicated	in	dendritic	spine	function	(Schratt	et	al.	2004),	and	upregulation	of	the	
cytoskeletal	 protein	 Arc	 (Yin	 et	 al.	 2002).	 BDNF	 also	 increases	 neurotransmitter	 release	 from	
presynaptic	terminals,	which,	along	with	stabilisation	of	synapses,	results	in	an	increase	in	neuronal	
activity.	In	turn,	neuronal	firing	causes	upregulation	of	bdnf	expression	via	increased	calcium	influx.	
Neuronal	 activity	 results	 in	 an	 increase	 in	 intracellular	 cAMP.	 In	 the	hippocampus	 cAMP	 regulates	
BDNF	 downstream	 effects	 by	 modulating	 BDNF	 phosphorylation	 of	 TrkB	 as	 well	 as	 modulating	
membrane	 recruitment	of	 TrkB,	possibly	 through	 strengthening	 the	 connection	between	TrkB	and	
Post-synaptic	 density	 95	 (PSD-95)	 (Ji	 et	 al.	 2005).	 PSD-95	 is	 recruited	 to	 dendrites	 through	 BDNF	
signalling	via	the	PI3K-Akt	pathway	(Yoshii	and	Constantine-Paton	2007),	which,	 in	turn,	stimulates	














of	 protein.	 Consequently,	 conclusions	 cannot	 be	 drawn	 regarding	 the	 relative	 levels	 of	 pro-









Figure 1.6. Levels of neurotrophins and their receptors in the rat retina. mRNA levels of (A) 
neurotrophin receptors and (B) their ligands from whole retinas following injury to induce high IOP. 









P75NTR	 is	 upregulated	 following	 injury	 (Ernfors	 et	 al.	 1989;	 Beattie	 et	 al.	 2002)	 and	 in	 disease,	
particularly	where	neuroinflammation	 is	a	component	of	 the	disorder,	such	as	Alzheimer’s	disease	
(Mufson	and	Kordower	1992)	and	multiple	sclerosis	(Dowling	et	al.	1999).	Levels	of	proneurotrophins	
have	 also	 been	 found	 to	 be	 increased	 in	 diseases	 affecting	 the	 CNS.	 Pro-NGF	 is	 upregulated	 in	
Alzheimer’s	disease	 (Fahnestock	et	al.	2001),	and	CNS	 injury	 (Beattie	et	al.	2002;	Harrington	et	al.	
2004).	There	is	evidence	that	in	depression	pro-BDNF	and	p75NTR	are	upregulated,	whilst	mature	BDNF	
and	TrkB	are	downregulated	(Zhou	et	al.	2013).	
Reduced	 expression	 and	 protein	 levels	 of	 TrkB	 and	 its	 ligands	 have	 been	 reported	 in	 a	 range	 of	
neurological	 disorders.	 Rett	 syndrome	 patients	 and	 the	Mecp2-null	 mouse	 model,	 have	 reduced	
expression	of	BDNF	(Wang	et	al.	2006;	Abuhatzira	et	al.	2007).	Schizophrenia	and	bipolar	disorder	are	
associated	with	decreased	mRNA	expression	levels	of	bdnf	and	trkb	(Weickert	et	al.	2003;	Ray	et	al.	
2014).	 In	 Huntington’s	 disease	 BDNF	 signalling	may	 be	 impaired	 (Baydyuk	 and	 Xu	 2014).	 There	 is	
evidence	 that	mutations	 in	 the	 gene	 encoding	 NT-4	may	 be	 a	 risk	 factor	 for	 primary	 open-angle	




the	catalytic	 form	of	TrkB	are	decreased	 in	 the	 temporal	and	 frontal	 cortex	 in	Alzheimer’s	disease	
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prefrontal	 cortex	 and	 hippocampus	 the	 normal	 ratio	 of	 pro-BDNF:BDNF	 is	 1:1	 (Tang	 et	 al.	 2014).	
Because	the	signalling	pathways	of	the	2	forms	of	BDNF	have	opposing	effects,	it	may	be	that	the	ratio	














importance	 of	 sortilin	 in	 BDNF	 processing.	 Paradoxically,	 although	 a	 decline	 in	 activity-dependent	






attractive	 enzymes	 to	 target	 is	 the	 serine	 protease,	 tPA.	 TPA	 cleaves	 the	 precursor	 peptide	
plasminogen	to	form	plasmin,	which	is	then	available	to	process	pro-BDNF	into	BDNF.	Reduced	plasma	
levels	of	tPA	and	BDNF	are	associated	with	depression	(Shi	et	al.	2010),	although	this	study	did	not	















FDA-approval	 for	 the	 treatment	of	numerous	conditions,	 including	 ischemic	stroke	and	myocardial	




















in	 transcription	 level	 of	bdnf	 in	 both	 the	 stressed	and	normal	 groups.	 The	 increase	 in	bdnf	mRNA	
correlated	with	increased	transcription	levels	of	the	anti-apoptotic	protein	Bcl-xl	with	exercise	(Jiang	














treatment	due	 to	 its	physical	properties:	 it	has	a	very	 short	half-life	 (T1/2<1	minute);	 it	 crosses	 the	
blood-brain	 barrier	 poorly	 (Poduslo	 and	 Curran	 1996);	 it	 is	 pharmacologically	 ‘sticky’	 (its	 highly	
positively	charged	residues	restrict	its	dispersion)	(Lu	2003);	and	it	has	some	affinity	for	p75NTR.	
Vector-based	delivery	of	BDNF	is	a	method	to	provide	sustained	supply	of	BDNF	to	the	target	tissue	







unbinding	 efficiency	 (TOFF),	 improve	 blood	 brain	 barrier	 crossing	 (by	 making	 the	 molecule	 more	
lipophilic	or	creating	a	caging	structure),	or	decrease	degradation	time	(T1/2).	Mimetics	may	also	be	






























PNN	 may	 protect	 neurons,	 particularly	 those	 with	 high	 activity	 levels,	 from	 oxidative	 stress	 and	
glutamate-induced	 excitotoxicity	 (Morawski	 et	 al.	 2004).	 Finally,	 CSPGs	 have	 been	 found	 to	 have	


















play	 roles	 in	synaptic	plasticity,	 remodelling,	angiogenesis,	as	well	as	 recruitment	of	 immune	cells.	










around	 the	 site	 of	 injury	 to	 protect	 nearby	 cells	 from	 inflammation	 and	 invading	 macrophages.	

























et	 al.	 2000)	 or	 upregulating	 neurotrophin	 receptors	 (Cui	 et	 al.	 2002),	 complete	 repair	 following	
moderate	to	severe	injury	is	rare.	In	these	cases,	therapeutic	approaches	are	required	to	replace	lost	
neurons,	 or	 to	 stimulate	 endogenous	 repair	mechanisms.	One	method	 is	 to	 stimulate	 the	 neurite	
outgrowth	of	resident	neurons.	This	can	be	attempted	by	application	of	growth	factors	(Thanos	et	al.	









positively	 charged	 growth	 cone	 of	 axons,	 and	 present	 an	 obstacle	 for	 synaptic	 and	 dendritic	
remodelling.	 CSPGs	 in	 the	 PNN	 and	 glial	 scars	 can	 be	 partially	 digested	 by	 the	 bacterial	 enzyme	
chondroitinase	 (ChABC)	 (Bradbury	 et	 al.	 2002).	 ChABC	 cleaves	 chondroitin	 sulphate	
glycosaminoglycan	 (GAG)	chains	 (the	main	 inhibitory	components	of	 the	molecules)	 to	 leave	stubs	






Figure 1.7. Basic structure of CSPG (top) with interaction points. Multiple CS-GAGs may be present 
but only one is shown for clarity. GAGs can be digested using the bacterial enzyme ChABC, leaving 
epitope stubs on the core protein (below). Note that ChABC digestion removes the inhibitory sulphate 
chains. G1, globular N-terminal domain; G3, globular C-terminal domain; PTPσ, protein tyrosine 
phosphatase σ; NCAM, neural cell adhesion molecule; Ig, immunoglobulin; EGF, epidermal growth 
factor; CRD, carbohydrate recognition domain; CBP, complement binding protein. Modified from 
(Bartus et al. 2012). 
Chapter	1:	Introduction	 58	
Degradation	of	GAG	chains	with	ChABC	 increases	the	 integration	efficiency	of	 transplanted	cells	 in	
spinal	cord	and	brain	injury	models.	ChABC	treatment	has	been	shown	to	increase	axonal	regeneration	
following	spinal	cord	injury	in	rats	(Bradbury	et	al.	2002;	Massey	et	al.	2006;	Garcia-Alias	et	al.	2009).	
On	the	other	hand,	 improvement	 in	visual	cortex	plasticity	was	 limited	following	ChABC	treatment	
with	 monocular	 deprivation	 in	 cats	 (Vorobyov	 et	 al.	 2013),	 suggesting	 that	 the	 success	 of	 CSPG	
digestion	may	be	 injury-specific,	 or	may	 require	 combination	 therapy.	 It	 has	been	postulated	 that	
ChABC	 treatment	may	 be	 effective	 in	 increasing	 integration	 of	 stem	 cells	 in	 retinal	 degeneration	





treatment	alone	 resulted	 in	an	8-fold	 increase	 in	 transplanted	 cell	 integration	 relative	 to	 controls.	
When	combined	with	a	siRNA	targeting	ZO-1	to	disrupt	the	OLM,	ChABC	treatment	also	significantly	
increased	 the	 percentage	 integration	 relative	 to	 control.	 However,	 one	 should	 interpret	 the	 data	
cautiously	as	it	is	not	clear	that	the	combined	treatment	offers	a	worthwhile	increase	in	percentage	
integration,	 relative	 to	 ChABC	 treatment	 alone.	 Optokinetic	 head-tracking	 behaviour	 experiments	
were	 used	 to	 assess	 how	 percentage	 integration	 relates	 to	 improved	 visual	 function.	 These	
















this	method	has	had	 limited	success.	Several	groups	claim	 improved	visual	acuity	 (MacLaren	et	al.	
2006;	Pearson	et	al.	2012),	however	this	is	frequently	proposed	upon	the	incorrect	assumption	that	
the	improved	light	sensitivity	of	photoreceptors	results	 in	 increased	neuronal	processing.	Neuronal	








There	 are	 several	 different	 stem/progenitor	 cell	 niches	 have	 been	 investigated	 for	 use	 with	 cell	















for	 the	 treatment	 of	 AMD.	 It	 should	 be	 noted,	 however,	 that	 transplantation	 and	 integration	 of	
neuronal	 cells,	 as	 opposed	 to	 epithelial	 cells	 described	 here,	 is	 likely	 to	 be	 a	 substantially	 greater	
challenge	for	the	future.	ESCs	also	offer	a	virtually	limitless	supply	of	cells	that	can	be	differentiated	








theory	 be	 derived	 from	 the	 patient’s	 own	 cells,	 creating	 an	 explosion	 in	 the	 field	 of	 personalised	




therefore	 the	 affected	 gene	must	 be	 corrected	prior	 to	 generation	of	 iPSCs	 (Tibbetts	 et	 al.	 2012).	
Despite	 these	 drawbacks,	 iPSCs	 have	 proved	 an	 invaluable	 research	 tool	 for	 modelling	
neurodegenerative	disorders,	including	ALS	(Dimos	et	al.	2008),	Rett	Syndrome	(Marchetto	et	al.	2010)	
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	NSCs	 have	 proved	 useful	 for	 researching	 genes	 and	 signalling	 pathways	 implicated	 in	
neurodegenerative	 disorders.	 It	 has	 been	 recently	 reported	 that	 the	 forced	 expression	 of	 three	
transcription	factors,	Brn2,	Ascl1	and	Myt1l,	can	convert	fibroblasts	to	induced	neuronal	cells	(Pang	
et	al.	2011).	This	is	a	faster	method	of	producing	neuronal	cells	from	somatic	cells,	therefore	this	may	











An	 alternative	 approach	 for	 patients	who	 have	 complete	 photoreceptor	 loss	 is	 transplantation	 of	
retinal	sheets.	Embryonic	retinal	sheets	have	been	transplanted	into	retinal	degeneration	models	but	
may	stimulate	formation	of	a	glial	scar	(Peng	et	al.	2007).	Foetal	retinal	sheets,	with	attached	RPE,	are	
able	 to	 integrate	 into	 the	host	 IPL	 (Woch	et	 al.	 2001)	 and	 in	 some	 cases	 have	been	evidenced	 to	
increase	light	sensitivity	(Sagdullaev	et	al.	2003;	Seiler	and	Aramant	2012),	while	in	others	little	effect	
on	visual	function	was	measured	(Seiler	et	al.	2009).	Greater	success	has	been	achieved	with	retinal	
sheets	 that	 contain	 both	 photoreceptors	 and	 RPE	 because	 the	 RPE	 is	 required	 to	 support	
photoreceptors.	More	recently,	retinal	sheets	constructed	from	ESCs	and	iPSCs	have	been	shown	to	













focuses	 on	 photoreceptor	 transplantation.	 One	 approach	 involves	 the	 transplantation	 of	Nrl-GFP	
labelled	post-mitotic	photoreceptor	precursor	cells	into	the	OLM	of	wildtype	mice.	This	is	a	promising	
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method,	 but	 will	 likely	 be	 more	 successful	 if	 the	 efficiency	 can	 be	 improved.	 The	 current	
transplantation	efficiency	is	0.01%	and	the	percentage	integration	is	even	lower	(Ma	et	al.	2011).	If	
sufficient	 cell	 numbers	 could	 be	 introduced	 into	 the	 retina,	 the	 result	 could	 be	 therapeutically	
beneficial,	however	it	has	been	estimated	that	150,000	cells	are	required	to	produce	an	ERG	response	
across	 the	 whole	 retina	 (Pearson	 et	 al.	 2012).	 Despite	 this,	 the	 question	 remains	 as	 to	 whether	






endeavour	 to	 improve	 methods	 to	 measure	 connectivity	 of	 transplanted	 cells,	 and	 also	 develop	





















Different	 models	 of	 retinal	 degeneration	 have	 different	 characteristics	 regarding	 speed	 of	
degeneration,	extent	of	OLM	disruption,	and	gliosis	(Barber	et	al.	2012).	Since	all	of	these	factors	affect	

























(McCaig	 et	 al.	 2005).	 In	 fact,	 endogenous	 electric	 fields	 have	 shown	 to	 be	 important	 for	 guiding	
mesenchymal	stem	cells	to	wound	sites,	including	the	rat	cornea	(Reid	et	al.	2005;	Zhao	et	al.	2006),	







































magnetic	 nanoparticles	 have	 the	 property	 of	 superparamagnetism:	 in	 the	 absence	 of	 an	 external	
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magnetic	field	mnps	have	a	magnetisation	value	of	essentially	zero;	and	in	the	presence	of	an	external	










to	 the	particle	surface	via	electrostatic	 interactions.	The	DNA-coated	particles	are	 then	 introduced	
into	cells	with	the	use	of	an	external	magnetic	field.	Advances	in	this	technology	have	shown	that	an	





Figure 1.8 Structure of a magnetic nanoparticle. The ferrite core (comprised of iron oxides plus a 
mixture of oxides of nickel, manganese and zinc) is surrounded by a silica coat, to which functional 








been	 used	 to	 deliver	 magnetic	 discs	 (2	 µm	 diameter)	 with	 an	 external	 magnetic	 field	 to	 cause	
mechanical	 destruction	 of	 malignant	 glioma	 cells	 (Muroski	 et	 al.	 2016).	 These	 treatments	 are	
attractive	since	the	procedure	is	non-invasive	and	the	particles	can	be	easily	tracked	using	MRI	(Mejias	
et	 al.	 2011).	 Further,	 by	 combining	 knowledge	 about	 specific	 cancer	 cell	markers,	mnps	 could	 be	
targeted	to	cancer	cells	using	cell	type-specific	antibodies	(Babincova	et	al.	2002).	This	would	mean	

























the	 investigation	 of	 signalling	 pathways.	 In	 addition,	 the	 protein	 concentration,	 using	 knowledge	
about	 the	number	of	mnps	per	protein,	and	the	spatiotemporal	effects,	using	controlled	magnetic	
fields,	 may	 be	 explored.	 Further,	 conjugation	 of	 mnps	 to	 ligands/agonists	 may	 enable	 magnet-
controlled	 manipulation	 of	 signalling	 cascades,	 which	 may	 be	 useful	 as	 a	 research	 tool	 and	 as	 a	
potential	therapeutic	approach.	It	should	be	noted	that	although	some	signalling	pathways,	such	as	






(Song	 et	al.,	 2010).	By	applying	 the	 same	principle	as	 is	used	 in	 cell	 sorting,	 resident	 cells	may	be	
controlled	using	a	magnet	by	using	antibody-conjugated	mnps.	Permanent	magnet-directed	migration	










fields	 decreases	 exponentially	 as	 a	 function	 of	 distance	 from	 the	 magnet	 surface	 (Figure	 1.9).	




























of	bird,	 including	homing	pigeons	 (Leask	1977;	Mora	et	 al.	 2004).	 There	have	been	 three	possible	
mechanisms	 for	 magnetoreception	 proposed:	 electromagnetic	 induction,	 magnetite	
magnetoreception,	and	chemical	magnetoreception.	Electromagnetic	induction	is	proposed	to	involve	
detection	 of	magnetic	 fields	 using	 an	 electrical	 conductor.	When	 the	 conductor	 passes	 through	 a	
magnetic	 field,	 a	 force	 Is	 applied,	 termed	 Lorentz	 force,	 the	magnitude	of	which	 is	 relative	 to	 the	
parameters	 (strength,	 direction,	 etc.)	 of	 the	 magnetic	 field	 (Johnsen	 &	 Lohmann	 2005).	 There	 is	
evidence	for	electromagnetic	induction	in	studies	with	elasmobranch	fish	(e.g.	sharks	and	rays),	for	
example	 rays	 conditioned	 to	 respond	 to	 changes	 in	 a	magnetic	 field	 had	 their	 responses	 blocked	
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following	introduction	of	magnets	in	their	nasal	cavities	(Molteno	&	Kennedy	2009).	Magnetite	(Fe3O4)	




are	 influenced	 by	 the	 Earth’s	 magnetic	 field.	 Since	 light-absorbing	 reactions,	 such	 as	 in	




There	 is	 little	 evidence	 for	 a	magnetoreceptor	 in	 non-migratory	 animals,	 however	 if	 it	 does	 exist,	
perhaps	the	alignment	of	a	molecule	with	the	geomagnetic	field	may	have	a	use	for	the	detection	of	
orientation	during	embryogenesis,	but	there	have	been	no	studies	supporting	this	theory.	Although	






to	 a	 permanent	 magnet	 array	 without	 mnps,	 which	 provides	 evidence	 of	 a	 mammalian	







The	 recent	 construction	of	 iron	 containing	proteins	has	brought	 the	 advent	of	magnetogenetics	 –	
control	of	transcription	by	the	application	of	an	external	magnetic	field.	Using	these	proteins,	neuronal	
action	potential	firing	(Long	et	al.	2015)	and	calcium-regulated	insulin	release	(Leibiger	and	Berggren	






























biolistics)	 (Lo	et	al.	1994;	Christianson	and	Lo	2011)	 labels	cells	 in	a	 sparse	manner.	Diolistics	uses	
tungsten	particles	as	microcarriers	of	lipophilic	dyes,	which	are	delivered	to	cells	under	high	pressure	
helium	blasts.	The	lipophilic	dyes	diffuse	through	cell	membranes	in	a	temperature-dependent	nature,	







Since	 the	 retinal	 explant	 is	 an	 axotomy	model,	 it	 is	 important	 to	 consider	 the	 potential	 signalling	
pathways	initiated	by	axotomy	that	may	contribute	to	dendritic	retraction	and	neuronal	cell	death	in	
this	 model.	 Wallerian	 degeneration	 describes	 the	 degenerative	 events	 contributing	 to	 axotomy-
induced	 axonal	 retraction	 (Gerdts	 et	 al.	 2016).	 The	 study	 of	Wallerian	 degeneration	 has	 provided	
target	proteins	and	signalling	cascades	that	would	be	interesting	to	study	in	the	context	of	dendritic	




independently	 activated	 by	 high	 intracellular	 levels	 of	 calcium	 (George	 et	 al.	 1995).	 In	 axotomy	












sensitive	 readout	 of	 neuronal	 cell	 health,	 compared	 to	 cell	 counts.	 Further,	 I	 postulate	 that	 the	








• To	 investigate	 the	 potential	 inhibitory	 role	 of	 the	 PNN	 on	 neuronal	 plasticity;	 specifically,	
whether	PNN	digestion	will	facilitate	dendritic	remodelling	of	RGCs	following	axotomy.		
• To	test	whether	external	magnetic	fields	can	increase	migration	depth	of	NSCs	into	the	GCL	of	
































Mice	were	 killed	 by	 cervical	 dislocation	 in	 accordance	with	 the	 Home	 Office	 (UK)	 and	 eyes	 were	
marked	for	nasal	orientation	using	a	sterile	18	gauge	needle.	Eyes	were	enucleated,	washed	with	1x	
phosphate-buffered	saline	(PBS,	pH	7.4)	to	remove	blood	and	hair,	and	placed	into	 ice-cold	Hanks-
balanced	 Salt	 Solution	 (Life	 Technologies	 Ltd.,	 Paisley,	 UK)	 supplemented	 with	 1%	 penicillin-
streptomycin.	Under	a	light	dissecting	microscope	(Leica	DFC	420C)	the	retina	was	rapidly	dissected	
as	outlined	in	Figure	2.1.	The	prepared	explant	was	cultured	on	a	0.4	µm	PTFE	culture	insert	(Millipore,	










Table 2.2. Components of culture media. All components were purchased from Life Technologies Ltd. 




















Figure 2.1. Preparation of retinal explant. (A) A cut was made from the nasal mark towards the optic 
nerve head and the anterior chamber was removed by cutting around the ciliary margin zone. (B) The 
lens was removed. (C) The retina was gently separated from the retinal pigment epithelium. (D) The 
retina was transferred to a culture insert, GCL facing up. Two additional cuts were made to create a 

























To	 visualise	 chondroitin	 sulphate	 (CS)	 digestion	 explants	 were	 treated	with	 ChABC,	 and	 after	 1	 d	
explants	 were	 fixed	 and	 processed	 for	 immunohistochemistry	 as	 described	 in	 section	 2.5.	 To	
investigate	the	effect	on	RGC	dendritic	morphology	explants	were	treated	with	ChABC	for	1	d	and	
cultured	for	a	further	2	d	(3	d	total)	or	5	d	(6	d	total),	and	at	the	end	of	the	culture	period	explants	


















at	 4°C.	 Explants	 were	 then	 carefully	 placed	 into	 moulds	 containing	 optimal	 cutting	 temperature	
compound	 and	 labelled	 for	 orientation.	 Explants	 were	 rapidly	 frozen	 using	 liquid	 nitrogen-cooled	
isopentane	and	stored	at	-20°C.	
Explants	were	cut	using	a	cryostat	(Leica	CM	3050S).	Sagittal	sections	were	cut	(10-14	µm)	in	the	nasal-
temporal	 direction	 and	 placed	 onto	 coated	 Superfrost®	 slides	 (Scientific	 Laboratory	 Supplies	 Ltd.,	
Yorkshire,	 UK).	 Slides	 were	 left	 covered	 at	 room	 temperature	 overnight	 to	 allow	 any	 water	 to	
evaporate,	and	then	stored	at	-20°C.	
To	use	as	positive	controls	for	apoptotic	markers,	spleen	from	mice	used	for	explants	were	dissected,	
washed	with	 saline	 and	 fixed	 overnight	 in	 4%	 PFA.	 The	 spleen	was	 cryoprotected	 in	 30%	 sucrose	





positive	 controls	 for	 neuronal/CS	markers,	 brains	 were	 fixed,	 frozen	 and	 section	 as	 described	 for	
spleen.	The	brains	were	cut	anterior	to	posterior	in	the	coronal	plane.	
2.4	Nuclear	staining	




























with	 1xPBS	 and	 then	 incubated	with	 primary	 antibody	 for	 4	 h	 or	 overnight	 at	 4°C.	 Sections	were	






















Table 2.3. Nuclear stains and antibodies used. 
Primary	antibodies	and	nuclear	stain	







































Nucleic	acids	 -	 -	 1	µM	 ddH2O	 Life	
Technologies	
Ltd.	









Goat	 4	µg/mL	 PBS	 Abcam	
Rabbit	IgG	 AlexaFluor	
488	












































Images	 were	 imported	 into	 FIJI	 and	 the	 central	 z-slice	 was	 analysed	 in	 each	 case	 to	 prevent	

































Figure 2.2. Locations imaged for calcein staining. X=0, Y=0 µm was set at the optic nerve and images 















mg	 1-1ʹ-dioctade-cyl-3,3,3ʹ,3ʹ-tetramethylindocarbocyanine	 perchlorate	 (DiI)	 and	 6	 mg	 3,3	
dioctadecyloxacarbocyanine	perchlorate	(DiO)	were	dissolved	in	800	µL	methylene	chloride	and	mixed	
with	half	of	the	tungsten	particles	to	coat.	DiI/DiO-coated	tungsten	particles	were	distributed	inside	







































Figure 2.3. Hand-held gene gun for ballistic delivery of lipophilic dye-coated tungsten particles 
(diolistics). The ‘bullets’ are loaded in the cartridge holder (white arrowhead). The particles are fired 
through a 3 µm filter (black arrowhead) into the retina (black arrow), with the barrel (white arrow) at a 






























Figure 2.4. 8-bit tracing of RGC with digitally overlain concentric (10 µm apart) circles centred on the 
soma centre for manual Sholl analysis. The number of dendrites on each ring were counted. Arrow 
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Where	,9:2 = 10	µ> 
 ,9?/ = 300	µ>		
 $ = 10	µ> 
 ./ −	 ./12 	> 0 
Equation 2.1. Branching index calculation. 
 
























Figure 2.5. Dendritic field area was measured in FIJI by drawing a polygon connecting the terminal 








































Retinas	were	 re-suspended	 in	 a	 total	 of	 300	 µL	 lysis	 buffer	 (3.5	mL	 RIPA	 buffer	 +	 35	 µL	 protease	
inhibitor	 +	 35	 µL	 phosphatase	 inhibitor	 +	 17.5	 µL	 6-amihexanoic	 acid	 +	 3.5	 µL	 aprotinin	 +	 3.5	 µL	



































Figure 2.6. Sandwich ELISA method. (A) The plate is coated with mAb#9. (B) After blocking, the 
homogenised sample tissue is added to the plate and the target protein (BDNF) binds to the antibody. 
(C) The detecting Ab (mAb#9 conjugated to HRP) is added and binds to BDNF. (D) The substrate 
(luminol) is added and HRP catalyses the oxidation of luminol into 3-aminophthalate. This reaction is 

























Table 2.4. Culture medium and supplements for NSC culture. 

























































Iron	 nanoparticles	 (100	 nm	 diameter;	 nTMag,	 Nanotherics	 Ltd.,	 Newcastle	 under	 Lyme,	 UK)	were	
introduced	into	the	NSCs	using	a	magnefect	nano	II	(Nanotherics).	1.5	µL	or	3	µL	mnps	were	inserted	
into	the	culture	medium	of	the	seeded	NSCs	and	the	35	mm	dish	was	placed	on	one	of	the	35	mm	
magnets	of	 the	6-well	 plate	magnefect	plate.	 The	magnefect	was	placed	at	37°C,	 5%	CO2	and	 the	
introduction	of	nanoparticles	into	the	cells	was	stimulated	for	30	min	using	0.2	mm	displacement	at	2	

















The	 magnetic	 field	 strengths	 for	 all	 the	 magnets	 at	 the	 distances	 used	 were	 measured	 using	 a	






Table 2.5. Magnet properties for migration of NSCs. All magnets are cylindrical. Flux density values 
from http://www.ndfeb-info.com/neodymium_grades.aspx, last accessed 27.02.16. 
Magnet	(grade)	 Diameter	(mm)	 Height	(mm)	 Residual	flux	
density,	Br	(mT)	
Pull-force	(kg)	
NdFeB	(N42)	 15	 8	 1280	 6.7	
NdFeB	(N42)	 30	 15	 1280	 23	
NdFeB	(N45)	 35	 20	 1320	 38	
Electromagnet	 18	 20	 -	 25	
 
	








Equation 2.2. Magnetic field strength, B, for permanent cylindrical magnets at a given distance from 







Figure 2.7. Hypothetical magnetic field strengths of all NdFeB magnets used as a function of distance 








magnet	 surface	 (6.7	 kg-pull	 magnet)	 or	 in	 the	 first	 900	 µm	 from	 the	 edge	 of	 the	 dish	 (all	 other	
magnets).	 The	 track	 data	 were	 then	 imported	 into	 Chemotaxis	 plugin	
(http://ibidi.com/xtproducts/en/Software-and-Image-Analysis/Manual-Image-Analysis/Chemotaxis-








Figure 2.8. The accumulated distance is calculated as the distance covered by a cell throughout its 
migration track. The euclidean distance is the straight-line distance connecting the start and end 





























this	 model	 has	 widespread	 applications.	 Further,	 short	 experimental	 time	 and	 the	 acquisition	 of	
translatable	data	are	major	advantages	of	the	explant	over	in	vivo	and	in	vitro	models,	respectively.	
The	primary	readout	for	this	model	is	typically	cell	loss,	which	fails	to	provide	information	regarding	
synaptic	 and	 structural	 changes	 to	 the	 cells	 prior	 to	 cell	 death,	 nor	 does	 it	 allow	 investigation	 of	
mechanisms	under	a	pathological	state.	The	lack	of	morphometric	data	is	a	major	limitation	of	this	
work	to	date.		
Predicated	on	widespread	evidence	 that	dendritic	pruning	precedes	cell	 loss	 in	neurodegenerative	














Figure 3.1. The branching index is an indicator of cell shape. A small branching index indicates a low 
number of branching events or that branching is predominantly proximal. A large branching index 
indicates a high number of branching events or that branching mainly occurs distally. Note that the two 
cells on the far right have the same number of dendrites, but due to different branching eccentricities 
they have very different branching indices. The branching index is calculated using Equation 2.1 (see 
Materials and Methods). 
	










extremely	 heterogeneous	 population	 of	 neurons;	 their	 shape	 varies	 with	 sub-type	 as	 well	 as	
eccentricity	(Sun	et	al.	2002;	Coombs	et	al.	2006).	In	order	to	reduce	bias,	it	is	essential	that	labelling	
is	random.	Techniques	such	as	the	use	of	transgenic	animals	that	rely	on	reporter	gene	expression	are	
inherently	 biased	 since	 they	 select	 for	 the	 healthiest	 cells	 that	 can	 afford	 the	 energy	 demands	 of	
translating	reporter	proteins.	Consequently,	the	unhealthiest	cells,	which	may	have	undergone	the	
greatest	 morphological	 changes,	 are	 less	 likely	 to	 express	 the	 reporter	 protein,	 thus	 resulting	 in	
underreporting	 of	 dendritic	 pruning,	 as	 demonstrated	 by	 Williams	 et	 al.	 (2013a).	 Further,	 the	
expression	of	Thy1,	a	commonly	used	driver	for	RGC-specific	expression,	has	been	found	to	be	both	
downregulated	(Huang	et	al.	2006)	and	upregulated	(Lee	et	al.	1998;	Astafurov	et	al.	2014)	following	
optic	nerve	 injury	or	 stress.	 Single	 cell	 filling	 is	 technically	 challenging	and	may	be	biased	 towards	
larger	cells.	Retrograde	labelling	commonly	results	in	dense	staining	patterns	and	requires	an	intact	
axon,	 which	may	 result	 in	 bias	 towards	 cells	 resistant	 to	 axonal	 degeneration	 or	 cells	 with	more	
efficient	 axonal	 transport	 machinery.	 Ballistic	 delivery	 of	 dye	 particles	 (diolistics)	 or	 plasmids	
(biolistics)	labels	cells	in	a	random	manner.	Since	biolistics	requires	a	2	d	incubation	period	to	permit	












Figure 3.2 Gross tissue area measurements of explants cultured for up to 14 d. (a) En face 
photographs of explants at each time point. (b) Mean areas of explants. P>0.05, ANOVA with TUKEY 

















Figure 3.3. Retinal cell layer measurements for explants cultured for up to 14 days, as shown. (a) 
Confocal images of TO-PRO-3 stained sagittal cryosections. (b) Nuclei counts for GCL (left) and 
measured thicknesses of INL (middle) and ONL (right). **P<0.005, ***P<0.001, ANOVA with TUKEY 
post-hoc (GCL and INL), Mann-Whitney with Bonferroni correction (ONL). Scale bar: 100 µm. Error 
bars: SEM. N=5 retinas (0 days), n=6 retinas (3 days), n=3 retinas (7 days), n=4 retinas (14 days). 
GCL=ganglion cell layer, INL=inner nuclear layer, ONL=outer nuclear layer. At least 3 sections from 



















Figure 3.4. Immunohistochemistry staining for the neuronal marker Thy1.2 and the apoptotic marker 
active caspase-3. (a) Frozen sections of retinas cultured for up to 14 d, as indicated. White arrows 
indicate active caspase-3 positive cells in magnified sections of the above images, as indicated. Scale 
bars: 100 µm (top and middle); 10 µm (bottom). (b) Quantification of Thy1.2 staining in each layer 
measured by mean green channel intensity. **P<0.005, ***P<0.001, ANOVA with TUKEY post-hoc. (c) 
The number of active caspase-3 positive cells in the GCL. (d) The number of active caspase-3 positive 
cells in the GCL expressed as a percentage of total number of cells in the GCL. (e) The number of 
active caspase-3 positive cells in the INL. (f) The number of active caspase-3 positive cells in the ONL. 
*P<0.05, Mann-Whitney with Bonferroni correction. Error bars: SEM. Thy1.2: n=3 retinas, 2 animals (0 
d); n=3 retinas, 3 animals (3 d); n=3 retinas, 3 animals (7 d); n=5 retinas, 5 animals (14 d). Active 
caspase-3: n=5 retinas, 3 animals (0 d); n=3 retinas, 3 animals (3 d); n=3 retinas, 3 animals (7 d); n=5 













Figure 3.5. TUNEL staining. (a) Frozen sections of retinal explants cultured for up to 14 d labelled for 
DNA breakdown using TUNEL assay. TUNEL positive cells are stained for both FITC (green) and TO-
PRO-3 nuclear stain (blue). Positive controls were sections pre-incubated in proteinase K for 1 hour. 
Negative controls had no incubation with Avidin-FITC. White arrows indicate TUNEL positive cells in 
magnified sections of the above images, as indicated. Scale bars: 100 µm (top), 10 µm (bottom). (b) 
Quantification of TUNEL staining in each layer measured by green channel fluorescence. *P<0.05, 
**P<0.005, ***P<0.001 (Mann-Whitney with Bonferroni correction). Error bars: SEM. N=4 retinas, 3 
















Figure 3.6. Calcein staining. (a) En face images of retinal wholemounts stained with calcein (green) 
and TO-PRO-3 (blue) immediately after dissection (0 d) and after 1, 7 and 14 days in culture, as 
indicated. Cells stained for both calcein and TO-PRO-3 were counted in the central 300x300 µm, as 
shown. Scale bars: 100 µm. (b) Quantification of calcein staining measured as number of calcein 
positive cells per mm2 at the same locations in each explant (x=1000 µm, y=850 µm; x=1000 µm, y=-
850 µm; x=-1000 µm, y=-850 µm; x=-1000 µm, y=850 µm where the origin is the optic nerve as 
described in Figure 2.2). Error bars: SEM. N=4 retinas, 4 animals (0 d), n=3 retinas, 3 animals (1 d), 





























Figure 3.7 (previous page). Morphometric analysis of RGCs. (a) Representative fluorescent images 
of RGCs labelled by diolistics after 0 days, 6 hours, 1 day, 2 days, and 3 days explant culture, as shown. 
Images are 512x512 pixels (0 d) or 1024x1024 pixels (rest). Scale bars: 100 µm. Arrows indicate axons. 
(b) Locations of all analysed RGCs at each time point where the origin in the optic nerve. All plots show 
no evidence of bias in terms of eccentricity. (c) Diagram of prepared explant for orientation of location 
plots. D = dorsal, T = temporal. Scale bar: 1 mm. (d) Sholl profiles for RGCs at each time point, with 
the number of cells indicated. (e) Sholl AUC at each time point calculated using the trapezoidal model. 
(f) Branching index for RGCs at each time point, calculated using the Sholl analysis output as described 
in chapter 2.8.5. (g) Sholl AUC plots for ON stratifying cells only. N=28 cells (0 d), n=14 cells (6 h), n=13 
cells (1 d), n=26 cells (2 d), n=28 cells (3 d). (h) Sholl AUC plots for OFF stratifying cells only. N=12 
cells (0 d), n=4 cells (6 h), n=8 cells (1 d), n=8 cells (2 d), n=5 cells (3 d). (i) Sholl AUC plots for ON-
OFF stratifying cells only. N=11 cells (0 d), n=6 cells (6 h), n=11 cells (1 d), n=7 cells (2 d), n=4 cells (3 
d). *P<0.05, **P<0.005, ***P<0.001 (Mann-Whitney tests with Bonferroni correction for all Sholl AUC; 
















Table 3.1. Proportion of RGC sub-types from 0 d explants classified according to Sun et al., 2002. 
Group	 Number	 %	of	population	 %	in	Sun	et	al.	
A1	 2	 3.3	 4.5	
A2	 8	 13.1	 5.5	
Total	A	 10	 16.4	 10.0	
B1	 4	 6.6	 4.5	
B2	 2	 3.3	 9.0	
B3	 11	 18.0	 10.6	
B4	 3	 4.9	 5.7	
Total	B	 20	 32.8	 29.8	
C1	 1	 1.6	 3.1	
C2	 8	 13.1	 10.2	
C3	 0	 0.0	 2.4	
C4	 2	 3.3	 5.9	
C5	 3	 4.9	 11.2	
C6	 4	 6.6	 4.5	
Total	C	 18	 29.5	 37.3	
D1	 3	 4.9	 7.3	
D2	 10	 16.4	 15.5	
















Table 3.2. Multiple regression model exploring predictive factors of Sholl AUC (dependent variable). In 
this model culture period (0=0 d, 1=6 h, 2=1 d, 3=2 d, 4=3 d), age (number of months), and sex (1=male, 










To	explore	 the	 involvement	of	pan-caspase	activation	 in	dendritic	atrophy	of	RGCs	and	to	 test	 the	






Kruskal-Wallis),	 indicating	 an	 effect	 on	 proximal	 dendrites	 only.	 Although	 none	 reached	 statistical	
significance	(P>0.05),	all	three	morphometric	parameters	measured	(Sholl	AUC,	branching	index	and	
dendritic	 field	 area)	 showed	 the	 trend	 of	 an	 increase	 with	 Q-VD	 treatment,	 relative	 to	 controls,	
although	all	measurements	for	control	and	Q-VD-treated	cells	were	significantly	reduced	(P<0.001,	

















Figure 3.8 (previous page). Morphometric analysis of RGCs treated with the pan-caspase inhibitor Q-
VD over 2 d. (a) Representative fluorescent images (left) of diolistically labelled RGCs and their 
respective 8-bit tracing images (right) from explants treated with Q-VD or vehicle only as control. Arrows 
indicate axons. Scale bars: 100 µm. (b) Locations of all analysed cells in each treatment group plotted 
relative to the optic nerve (origin). Neither group displayed any sign of bias in terms of eccentricity. (c) 
Sholl plots for both treatment groups with the number of cells analysed for each group shown *P<0.05, 
Kruskal-Wallis. (d) Sholl AUC for both treatment groups shown with the value for 0 d cells for 
comparison. ***P<0.001, ANOVA with TUKEY post-hoc. (e) Branching index for both treatment groups 
shown with the value for 0 d cells for comparison. ***P<0.001, ANOVA with TUKEY post-hoc. (f) 
Dendritic field area for both treatment groups shown with the value for 0 d cells for comparison. 
***P<0.001, ANOVA with TUKEY post-hoc. (g) Experimental time scale. (h) Sholl AUC plots for ON 
stratifying cells only. N=28 cells (0 d), n=2 cells (control), n=10 cells (Q-VD). *P<0.05, **P<0.005, 
ANOVA with TUKEY post-hoc. (i) Sholl AUC plots for OFF stratifying cells only. N=12 cells (0 d), n=9 
cells (control), n=13 cells (Q-VD). **P<0.005, ***P<0.001, ANOVA with TUKEY post-hoc. (j) Sholl AUC 
plots for ON-OFF stratifying cells only. N=11 cells (0 d), n=0 cells (control), n=1 cell (Q-VD). *P<0.05, 
ANOVA. Error bars: SEM.	
In	order	to	check	that	age	was	not	a	confounding	factor,	a	multiple	regression	analysis	was	run	on	
Sholl	AUC	 values	 for	Q-VD-treated	 cells.	 The	model	was	 a	 good	 fit	 of	 the	data	 (p<0.005,	ANOVA).	





Table 3.3. Multiple regression model exploring predictive factors of Sholl AUC (dependent variable). In 



























associated	 with	 normal	 DNA	 turnover	 and	 necrosis	 (Elmore	 2007),	 the	 latter	 of	 which	 has	 been	
reported	to	be	a	major	cause	of	cell	death	in	axotomy	models	(Kashimoto	et	al.	2008).	Additionally,	
active	caspase-3	may	not	be	a	reliable	marker	of	apoptosis,	particularly	as	 it	 remained	constant	 in	
every	cell	layer,	other	than	the	ONL.	This	suggests	that	active	caspase-3	was	not	implicated	in	cell	loss	





staining	reported	here	could	 indicate	that	cell	death	occurred	rapidly,	 i.e.	the	period	 in	which	cells	
were	undergoing	apoptosis	and	would	be	 labelled	as	 such	was	 so	 short	 that	 cells	either	appeared	
healthy	or	were	completely	degraded,	however	this	seems	unlikely	since	cell	loss	in	the	GCL	was	not	
significant	 until	 14	 days.	 A	 more	 plausible	 explanation	 is	 that	 caspase-independent	 cell	 death	
pathways	had	been	triggered,	resulting	 in	DNA	damage,	but	cell	death	did	not	begin	to	occur	until	
after	7	days.	These	data	 support	 the	use	of	 cell	 loss	 to	quantify	 cell	death.	The	 lack	of	 supporting	
calcein	staining	is	likely	due	to	poor	tissue	penetration	and	therefore	would	require	future	validation	
–	 calcein	 staining	may	be	more	appropriate	 to	 test	 viability	 in	 cell-based	assays	 rather	 than	 tissue	
preparations.	Although	it	has	been	reported	in	the	rat	retinal	explant	(Grieshaber	et	al.	2010),	calcein	








any	 difference	 in	 morphology	 is	 not	 due	 to	 sub-type	 bias.	 Labelling	 bias	 can	 be	 discounted	 here	
because	the	distribution	of	sub-types	identified	at	0	d	closely	matched	that	reported	by	Sun	et	al.	(Sun	
et	 al.	 2002).	Other	 factors,	 such	 as	 age	 and	 sex	 of	 the	 animal,	 can	 be	 discounted	 as	 confounding	
factors,	since	culture	time	or	treatment	group	were	found	to	be	the	only	predictive	factors	of	dendritic	
arbor	morphology	(for	0-3	d	cells).		
















explanations	 for	 this.	Firstly,	 the	number	of	cells	may	have	been	 insufficient	 for	a	difference	to	be	
measured.	Secondly,	2	days	may	not	have	been	a	long	enough	time	course	for	the	protective	effect	to	























degeneration	 (Fahnestock	et	 al.	 2002;	Weickert	 et	 al.	 2003;	Baydyuk	and	Xu	2014),	 therefore	one	
therapeutic	avenue	to	explore	is	the	restoration	of	normal	levels	of	BDNF	to	repair	neuronal	function.	
Although	 the	 levels	 of	 BDNF	 in	 the	 rodent	 retinal	 explant	 have	 been	 reported	 (Seki	 et	 al.	 2003;	
Domenici	 et	 al.	 2014),	 these	 have	 not	 been	 published	 in	 parallel	 with	 morphometric	 changes.	 I	
therefore	investigated	the	temporal	relationship	between	endogenous	BDNF	protein	levels	and	RGC	
dendritic	 retraction,	 and	 then	 to	 explore	 whether	 dendrite	 loss	 could	 be	 accelerated	 by	 blocking	
endogenous	BDNF.		

































Figure 4.1 Quantification of total protein (BCA assay) and BDNF protein (ELISA) in retinal explants 
after culture periods of up to 14 d. (a) Total protein. *p<0.05, **p<0.005, ***p<0.001, ANOVA. (b) Total 
BDNF protein levels. p>0.05, ANOVA. (c) BDNF protein relative to total protein. p<0.05, ANOVA. (d) 
BDNF protein relative to total protein, expressed as a percentage of the value at 0 d. n=6 explants, 3 
animals (0 d); n=6 explants, 3 animals (1 d); n=6 explants, 3 animals (3 d); n=6 explants, 3 animals (7 









4.2b-c).	 Following	 BDNF	 treatment,	 Sholl	 curve	 peaks	 were	 greatly	 increased	 20-80	 µm	 (p<0.05,	
Kruskal-Wallis)	 from	 the	 soma	 centre	 (Figure	 4.2d).	 BDNF	 treatment	 resulted	 in	 a	 75.8%	 increase	
(p<0.005,	ANOVA	with	Tukey	post-hoc)	 in	Sholl	AUC	and	an	81.0%	 increase	 (p<0.001,	ANOVA	with	





















Figure 4.2 (previous page) Morphometric analysis of RGCs from explants treated with 100 ng/mL 
BDNF for 3 d. (a) Culture timeline of experiment. (b) Fluorescent images (left) and 8-bit tracing images 
(right) of diolistically labelled RGCs. Scale bar: 100 µm. Arrows indicate axon. (c) Locations of all 
analysed RGCs relative to the optic nerve (origin). (d) Sholl profiles for control cells and BDNF-treated 
cells demonstrating increased dendritic complexity with BDNF treatment. The number of cells in each 
group is shown. *p<0.05, **p<0.005, ***p<0.001, Kruskal-Wallis. (e) Area under the Sholl profile for 
each group, shown with the value for 0 d cells for comparison. **p<0.005, ***p<0.001, ns not significant, 
test. (f) Branching index for each group, shown with the value for 0 d cells for comparison. ***p<0.001, 
ns not significant, test. (g) Dendritic field area for each group, shown with the value for 0 d cells. *p<0.05, 
**p<0.005, ***p<0.001, test. (h) Area under the Sholl profile for ON-stratifying cells in each group. 
**p<0.005, ***p<0.001, test. (i) Area under the Sholl profile for OFF-stratifying cells in each group. 

















Table 4.1. Multiple regression model to test the possible confounding effects of variance in age and sex 
on Sholl AUC (dependent variable). Culture condition (1=control, 2=BDNF), age (number of months), 














20-100	µm	 from	 the	 soma	 centre	 (p<0.05,	 Kruskal-Wallis)	 (Figure	 4.3d).	 The	 Sholl	 AUC	of	 delayed	
BDNF-treated	 cells	 was	 increased	 by	 136%	 (p<0.001)	 compared	 to	 controls,	 decreased	 by	 32.9%	
(p<0.05)	relative	to	0	d	cells,	and	increased	by	56.6%	(p<0.005,	ANOVA	with	Tukey	post-hoc)	compared	























Figure 4.3 (previous page) Morphometric analysis of RGCs from explants treated with 100 ng/mL 
BDNF initiated 3 d-post axotomy. (a) Culture timeline. (b) Fluorescent images (left) and 8-bit tracing 
images (right) of RGCs from each group. Scale bars: 100 µm. Arrows indicate axons. (c) Locations of 
all analysed RGCs relative to the optic nerve (origin) showing no evidence of labelling bias. (d) Sholl 
profiles for each group. The number of cells in each group is shown. *p<0.05, **p<0.005, ***p<0.001, 
Kruskal-Wallis. (e) Area under the Sholl profile, shown with the values for 0 d and 3 d cells for 
comparison. *p<0.05, **p<0.005, ***p<0.001, ns not significant, ANOVA with Tukey post-hoc. (f) 
Branching index with 0 d and 3 d cell values. *p<0.05, **p<0.005, ***p<0.001, ns not significant, ANOVA 
with Tukey post-hoc. (g) Dendritic field area with 0 d cell value. *p<0.05, **p<0.005, ***p<0.001, ns not 
significant, ANOVA with Tukey post-hoc. Areas under the Sholl profile split by RGC sub-type (i-k) 
provide no evidence of sub-type-specific effects of delayed BDNF treatment. (i) Sholl AUCs for ON 
cells, with the corresponding value for 0 d and 3 d cells for comparison. *p<0.05, ***p<0.001, ANOVA 
with Tukey post-hoc. (j) Sholl AUCs for OFF cells, with the corresponding value for 0 d and 3 d cells. 
**p<0.005, ***p<0.001, ANOVA with Tukey post-hoc. (k) Sholl AUCs for bistratified cells, with the 































Figure 4.4 (previous page) Morphometric analysis of RGCs from explants treated with 1000 ng/mL 
BDNF initiated at day 3. (a) Culture timeline. (b) Fluorescent images (left) and 8-bit tracings (right) of 
diolistically labelled RGCs in each treatment group. The number of cells in each group is shown. Scale 
bars: 100 µm. Arrows indicate axons. (c) Locations of all analysed cells relative to the optic nerve 
(origin) showing no evidence of labelling bias. (d) Sholl profile for each group. The number of cells in 
each group is shown. *p<0.05, **p<0.005, ***p<0.001, Kruskal-Wallis. (e) Area under the Sholl profile, 
shown with the values for 0 d and 3 d cells for comparison. ***p<0.001, ANOVA with Tukey post-hoc. 
(f) Branching index with 0 d and 3 d cell values. *p<0.05, **p<0.005, ***p<0.001, ANOVA with Tukey 
post-hoc. (g) Soma diameter. p>0.05, test. (h) Dendritic field area with 0 d cell value for reference. 








µg/mL)	 to	 block	 endogenous	 BDNF.	 To	 ensure	 that	 mAb#9	 was	 binding	 to	 its	 target	 protein,	 11	
explants	(n=10	animals	of	both	sex,	aged	2-5	months)	were	cultured	for	3	d	with	100	ng/mL	BDNF	±10	
µg/mL	mAb#9.	At	the	end	of	the	culture	period	RGCs	were	labelled	and	analysed	as	before.	The	culture	
timeline	 is	 shown	 in	Figure	4.5a.	There	was	no	visible	effect	of	mAb#9	treatment	on	 the	dendritic	


















Figure 4.5 (previous page) Morphometric analysis of RGCs from explants treated with BDNF blocking 
antibody mAb#9 or 100 ng/mL BDNF for 3 d. (a) Culture timeline. (b) Fluorescent images of diolistically 
labelled RGCs from each treatment group. Scale bars: 100 µm. Arrows indicate axons. (c) Locations of 
all analysed cells relative to the optic nerve (origin). (d) Sholl profiles for mAb#9-treated cells and control 
cells, showing no effect of blocking endogenous BDNF. p>0.05, Kruskal-Wallis. (e) Sholl profiles for 
BDNF-treated cells ±mAb#9, showing that mAb#9 treatment blocks the positive effect of exogenously-
applied BDNF. *p<0.05, Kruskal-Wallis. The number of cells in each treatment group (d-e) is shown. (f) 
Area under the Sholl profile for all treatment groups shows no difference between groups, except BDNF-
treated cells. **p<0.005, ANOVA	with	 Tukey	post-hoc. (g) Branching index for all groups. *p<0.05, 
**p<0.005, ANOVA	with	Tukey	post-hoc. (h) Soma diameter for each group. p>0.05, ANOVA	with	Tukey	







that	 endogenous	 BDNF	 does	 not	 play	 a	 role	 in	 the	 dendritic	 retraction	 of	 RGCs	 and	 that	 BDNF	
treatment	can	retard	RGC	dendrite	loss.	In	addition,	I	present	for	the	first	time	evidence	that	delayed	
application	 of	 BDNF	 can	 not	 only	 protect	 against	 dendritic	 retraction	 but	may	 stimulate	 dendritic	
outgrowth	in	RGCs.	




connections	 that	can	be	protected,	 therefore	may	be	 important	 to	consider	 for	 the	strategy	of	 re-
wiring	neuronal	networks	as	only	partial	restoration	of	neuronal	function	may	be	achievable.	
The	 evidence	 presented	 here	 is	 consistent	 with	 a	 neurite	 outgrowth	mechanism	 of	 BDNF.	 This	 is	
particularly	exciting	because	it	demonstrates	that	it	may	be	possible	to	treat	neuronal	degeneration	
even	after	a	significant	amount	of	neuronal	damage	has	occurred.	Application	of	a	compound	such	as	
BDNF	 could	 theoretically	 promote	 re-wiring	 of	 neuronal	 networks,	 thereby	 restoring	 neuronal	
function.	It	is	important	to	note	that	this	mechanism	of	BDNF	cannot	be	confirmed	with	the	results	
shown	here;	it	may	simply	be	a	consequence	of	biased	populations	of	cells.	As	outlined	in	section	1.2	









due	 to	 the	 low	 number	 of	 cells	 in	 some	 groups.	 Although	 this	 weakens	 the	 statistical	 power	 of	





measure	 the	 location	of	BDNF	within	 the	 retina.	 Secondly,	mAb#9	was	 shown	 to	block	exogenous	
BDNF,	 but	 if	 it	 could	 not	 penetrate	 the	 tissue	 sufficiently,	 it	 would	 have	 been	 unable	 to	 bind	
endogenous	 BDNF.	 In	 both	 cases,	 the	 possibility	 that	 endogenous	 BDNF	 secretion	 was	 reduced	
following	axotomy	cannot	be	discounted.	
4.8	Summary	





















after	 injury	 if	 neuronal	 function	 is	 to	 be	 repaired.	 It	 has	 been	 proposed	 that	 CSPG	 digestion	may	














ChABC,	 or	 vehicle	 as	 control,	 for	 1	 d.	 Explants	 were	 then	 fixed	 and	 processed	 for	
immunohistochemistry	to	visualise	presence	of	GAG	stubs	1B5,	2B6	and	3B3.	Antibodies	to	1b5,	2B6	














Figure 5.1 (previous page). Immunohistochemical staining for products of CSPG digestion in frozen 
sections of the retinal explant following 1 d treatment with 0.25 U/mL and 0.5 U/mL ChABC. CS stubs 
(1B5, 2B6 and 3B3) are visualised in green and nuclear staining (Hoechst) is displayed in monochrome 
above to the corresponding antibody staining panel. (a) Negative controls: retinal sections stained for 
the corresponding antibody with omission of either primary or secondary antibody displaying negligible 
fluorescence. (b) Positive controls (retina): explants were cultured under normal culture conditions for 
1 d and their sections were pre-incubated in 0.5 U/mL ChABC for 2 h at 37°C, 5% CO2 prior to 
immunohistochemical staining. (c) Positive controls (brain): untreated mouse brain sections to visualise 
normal levels of the CS stubs in the brain. (d) PBS control: an explant was cultured with a PBS aliquot 
for 1 d to visualise normal levels of each CS stub following 1 d ex vivo culture. N=1 explant. (e) An 
explant treated with 0.25 U/mL ChABC displays faint, dispersed staining for all epitopes in all retinal 
layers. N=1 explant. (f) Explants treated with 0.5 U/mL ChABC shows strong staining for 1B5 (left) and 
















characteristically	highly	branched,	but	 cells	with	 combined	BDNF	and	ChABC	 treatment	had	 fewer	




















Figure 5.2 (previous page) Morphometric analysis of RGCs from explants treated with 0.5 U/mL 
ChABC as a topical aliquot from day 0 for 1 d and cultured for 3 d. (a) Culture timeline. (b) 1024x1024 
pixel confocal images (top) and 8-bit tracings (bottom) of diolistically labelled RGCs from each treatment 
group show no visible difference between treatment conditions. Arrows indicate axons. Scale bars: 100 
µm. (c) Locations of all cells analysed relative to the optic nerve (origin) demonstrating no evidence of 
labelling bias. (d) Sholl profiles show no difference between treatment groups. p>0.05, Kruskal-Wallis. 







Figure 5.3 (previous page) Morphometric analysis of RGCs from explants treated with 100 ng/mL 
BDNF for 3 d, combined with 0.5 U/mL ChABC applied as a topical aliquot from day 0 for 1 d. (a) Culture 
timeline. (b) 1024x1024 pixel confocal images (top) and 8-bit tracings (bottom) of diolistically labelled 
RGCs from each treatment group show increased dendritic branching in the absence of ChABC. Arrows 
indicate axons. Scale bars: 100 µm. (c) Locations of all cells analysed relative to the optic nerve (origin) 
demonstrating no evidence of labelling bias. (d) Sholl profiles show increased number of dendrites 





Figure 5.4 Morphometric measures of RGCs from explants treated with 0.5 U/mL ChABC, or vehicle 
as control, ±100 ng/mL BDNF over 3 d. (a) Soma diameters show no difference between groups. 
p>0.05, ANOVA with Tukey post-hoc. Measures of dendritic arbor morphology (b-d) demonstrate a 
general trend of increased dendritic arbor complexity and size with BDNF –ChABC. (b) Dendritic field 
area for each group. p>0.05, ANOVA with Tukey post-hoc. (c) Area under the Sholl profile. *p<0.05, 

















6	 explants	 (n=3	 animals,	male,	 aged	 2-6	months)	were	 treated	with	 a	 topical	 aliquot	 of	 0.5	U/mL	
ChABC,	or	vehicle	as	control,	at	day	0,	followed	by	delayed	100	ng/mL	BDNF	treatment	(6	d	total).	The	

























Figure 5.5 (previous page) Morphometric analysis of RGCs from explants treated with 0.5 U/mL 
ChABC as a topical aliquot from day 0 for 1 d and cultured for 6 d. (a) Culture timeline. (b) 1024x1024 
pixel confocal images (top) and 8-bit tracings (bottom) of diolistically labelled RGCs from each treatment 
group. Arrows indicate axons. Scale bars: 100 µm. (c) Locations of all cells analysed relative to the 
optic nerve (origin) demonstrating no evidence of labelling bias. (d) Sholl profiles. *p<0.05, Kruskal-








Figure 5.6 (previous page) Morphometric analysis of RGCs from explants treated with 0.5 U/mL 
ChABC applied as a topical aliquot on day 0 for 1 d, followed by 100 ng/mL BDNF treatment for 3 d 
initiated at day 3 (6 d total). (a) Culture timeline. (b) 1024x1024 pixel confocal images (top) and 8-bit 
tracings (bottom) of diolistically labelled RGCs from each treatment group show no difference in 
morphology between groups. Arrows indicate axons. Scale bars: 100 µm. (c) Locations of all cells 
analysed relative to the optic nerve (origin) demonstrating no evidence of labelling bias. (d) Sholl 









Figure 5.7 (previous page) Morphometric measures of RGCs from explants treated with ±0.5 U/mL 
ChABC ±100 ng/mL BDNF over 6 d. (a) Soma diameters show no difference between groups. p>0.05, 
ANOVA with Tukey post-hoc. Measures of dendritic arbor morphology (b-d) demonstrate a general 
trend of increased dendritic arbor complexity and size with addition of BDNF or ChABC. (b) Dendritic 
field area for each group. *p<0.05, ANOVA with Tukey post-hoc. (c) Area under the Sholl profile. 
*p<0.05, **p<0.005, ANOVA with Tukey post-hoc. (d) Branching index. p>0.05, ANOVA with Tukey 
post-hoc. (e) Representative XY orthogonal views of dendritic arbors stratifying in the OFF lamina for 
cells treated with BDNF (top) or BDNF + ChABC (bottom). In each image lower black arrow indicates 
GCL, upper black arrow indicates INL, open arrow indicates stratification depth. Nuclei stained with TO-
PRO-3 (blue), dendrites stained with DiI (red) or DiO (green). (f) Quantification of stratification depth for 
ON and OFF-stratifying dendrites for cells treated with BDNF or BDNF + ChABC. Blue dotted line 







To	 test	 the	 effect	 of	 increased	 concentration	 of	 BDNF	 with	 ChABC	 treatment	 to	 see	 if	 the	
neuroprotective	effect	of	BDNF	could	be	enhanced.	Eleven	explants	(n=6	animals	of	either	sex,	aged	
6	weeks-2	months)	were	treated	with	a	topical	aliquot	of	0.5	U/mL	ChABC,	or	vehicle	as	control,	at	
day	 0,	 followed	 by	 1000	 ng/mL	 BDNF	 treatment	 initiated	 at	 day	 3	 for	 3	 d	 (6	 d	 total).	 RGCs	were	
















Figure 5.8 (previous page) Morphometric analysis of RGCs from explants treated with 0.5 U/mL 
ChABC, or vehicle as control, applied as a topical aliquot on day 0 for 1 d, followed by 1000 ng/mL 
BDNF treatment, or vehicle as control, initiated at day 3 for 3 d (6 d total). (a) Culture timeline. (b) 
1024x1024 pixel confocal images of diolistically labelled RGCs from each treatment group show 
dramatically increased dendritic arbor branching and size following BDNF treatment. Arrows indicate 
axons. Scale bars: 100 µm. (c) Locations of all cells analysed relative to the optic nerve (origin) 
demonstrating no evidence of labelling bias. (d) Sholl profiles. *p<0.05, **p<0.005, ***p<0.001, Kruskal-










In	order	 to	 test	whether	 reversal	 of	 treatment	order	 could	enhance	 the	neuroprotective	effect	of	



















Figure 5.9 (previous page) Morphometric analysis of RGCs from explants cultured for 3 d, treated with 
100 ng/mL BDNF at day 0 for 1d, followed by 0.5 U/mL ChABC treatment at day 1. (a) Culture timeline. 
(b) 1024x1024 pixel confocal images (left) and 8-bit tracings (right) of diolistically labelled RGCs from 
each treatment group. Arrows indicate axons. Scale bars: 100 µm. (c) Locations of all cells analysed 
relative to the optic nerve (origin) demonstrating no evidence of labelling bias. (d) Sholl profiles. 
*P<0.05, Kruskal-Wallis. The number of cells for each group is indicated. (e) Soma diameter. P>0.05, 
T-test. (f) Dendritic field area. P>0.05, T-test. (g) Area under the Sholl profile. P<0.05, T-test. (h) 

















of	 cells	 (especially	 in	 Figure	 5.9)	 and	 that	 it	 would	 be	 prudent	 to	 undertake	 further	 work	 to	
substantiate	these	observations.	Despite	this,	the	Sholl	profiles	were	similar	for	all	groups	of	the	same	
culture	period,	 therefore	 it	 is	 likely	 that	 there	was	a	 similar	 spread	of	cell	 types	 in	each	group.	All	
groups	seemed	to	show	the	same	trend,	but	these	patterns	should	be	validated	in	the	future	with	the	
use	of	time-series	imaging.	




Reversal	 of	 treatment	 timeline,	 i.e.	 BDNF	 prior	 to	 ChABC,	 may	 have	 been	 protective	 for	 distal	























I	 have	 demonstrated	 that	 BDNF	 application	 significantly	 retards	 RGC	 dendritic	 retraction	 in	 the	
degenerating	 retinal	 explant,	 therefore	 has	 potential	 for	 the	 treatment	 of	 neurodegenerative	
disorders.	Injection	of	BDNF	is	not	suitable	therapeutically	because	BDNF	is	pharmacologically	‘sticky’	
and	has	a	short	half-life,	therefore	it	is	difficult	to	control	concentration	and	location	of	injected	BDNF	
(Poduslo	 and	 Curran	 1996;	 Lu	 2003).	 Further,	 BDNF	 application	 is	 undesirable	 due	 to	 the	 risks	
associated	with	repeat	injections	in	the	CNS,	such	as	inflammation	or	infection.	An	alternative	delivery	
route	is	via	secretion	from	donor	stem	cells	that	can	be	engineered	to	translate	and	secrete	peptides	
of	 choice.	 Cell-mediated	 delivery	 enables	 sustained	 dosing	 of	 the	 agent	 and,	 more	 importantly,	





been	evidenced	 to	play	a	 role	 in	cell	migration	during	wound	healing.	Further,	magnetic	 fields	are	
deeply	penetrating	without	compromising	 safety,	and	permit	dosing	 to	be	controlled	 spatially	and	
temporally	(Kyrtatos	et	al.	2009;	Chen	et	al.	2013).	Magnetic	fields	also	have	the	advantage	of	allowing	









GFP-expressing	 NSCs	 (passage	 39-42)	were	 seeded	 onto	 10	 µg/mL	 laminin-coated	 35	mm	 culture	
dishes	 overnight	 at	 a	 density	 of	 1.2-1.8X105	 cells/cm2.	 Volumes	 of	 1.5	 uL	 or	 3	 uL	 nTMag	 were	
introduced	into	NSCs	using	a	magnefect	at	2	Hz	for	30	min	at	37°C,	5%	CO2.	Control	dished	contained	
NSCs	with	no	nTMag.	Cells	were	disassociated	from	laminin	using	Accutase®	and	immediately	imaged	









a	 particular	 direction,	 i.e.	 towards	 a	 magnet)	 of	 the	 movement	 paths	 of	 the	 NSCs	 in	 any	 of	 the	
conditions	investigated	(Figure	6.2).	There	was	no	difference	(p>0.05,	ANOVA	with	Tukey	post-hoc)	in	
migration	 distance	 between	 experimental	 conditions	 (Figure	 6.3a-b).	 Although	 no	 group	 was	








Figure 6.1 Experimental set-up for magnet-directed movement of magnetic nanoparticle-containing 
NSCs in suspension in vitro. (a) Magnetic field strength of each magnet measured using a gaussmeter 
at the surface of the magnet and at 1 mm increments up to 10 mm from the magnet surface. (b) GFP-
NSCs ±nTMag were placed in a 35 mm dish and the magnet was held directly against the edge of the 
dish (6.7 kg-pull magnet) or 10 mm from the edge of the dish (all other magnets). Cells were imaged by 
brightfield microscopy at the edge of the dish in the absence of the magnet before introduction of the 
magnet. Open arrow: light source. Black arrow: detector. The north (N) and south (S) poles are 
indicated. (c) Example image of NSCs after analysis with mTrack to show relative position of magnet. 










Figure 6.2 (previous page) Cell tracking analysis of GFP-NSCs with 6.7 kg-pull NdFeB magnet using 
the plugin mTrack. The start (top) and end (middle) frames are shown for each condition. The cell 
movement plots (bottom) show the migration track of each cell relative to its starting position (origin) 
created using the Chemotaxis plugin in FIJI. Magnet: right of each image, as indicated. (a) No magnet, 
no nTMag. (b) Magnet, no nTMag. (c) No magnet, 1.5 µL nTMag. (d) Magnet, 1.5 µL nTMag. (e) No 





Figure 6.3 Quantification of NSC tracking in the presence of a 6.7 kg-pull NdFeB magnet with 0 µL, 1.5 
µL or 3 µL nTMag. (a) Mean accumulated distance for each experimental condition. p>0.05, ANOVA 
with Tukey post-hoc. (b) Mean euclidean distance for each experimental condition. p>0.05, ANOVA 
with Tukey post-hoc. (c) Mean velocity for each experimental condition. p>0.05, ANOVA with Tukey 
post-hoc. (d) Mean x and y migration indices for each experimental condition. p>0.05, Mann-Whitney 
with Bonferroni correction (x forward index); p>0.05, ANOVA with Tukey post-hoc (y forward index). (e) 
Mean x and y centres of mass for each experimental condition. p>0.05, ANOVA with Tukey post-hoc. 




















Figure 6.4 (previous page) Cell tracking analysis of GFP-NSCs with 23 kg-pull NdFeB magnet using 
the plugin mTrack. The start (left) and end (right) frames are shown for each condition. The cell 
movement plots (bottom) show the migration track of each cell relative to its starting position (origin). 
(a) No magnet, no nTMag. (b) Magnet, no nTMag. (c) No magnet, 3 µL nTMag. (d) Magnet, 3 µL 








Figure 6.5 (previous page) Quantification of NSC movement tracking in the presence of a 23 kg-pull 
NdFeB magnet with 0 µL or 3 µL nTMag. (a) Mean accumulated distance for each experimental 
condition. p>0.05, ANOVA with Tukey post-hoc. (b) Mean euclidean distance for each experimental 
condition. p>0.05, ANOVA with Tukey post-hoc. (c) Mean velocity for each experimental condition. 
p>0.05, ANOVA with Tukey post-hoc. (d) Mean x and y migration indices for each experimental 
condition. *p<0.05, ANOVA with Tukey post-hoc. *represents 0 µL no magnet vs. 3 µL with magnet y 
forward migration index. (e) Mean x and y centres of mass for each experimental condition. p>0.05, 


















Figure 6.6 (previous page). Cell tracking analysis of GFP-NSCs with 38 kg-pull NdFeB magnet using 
the plugin mTrack. The start (left) and end (right) frames are shown for each condition. The cell 
movement plots (bottom) show the movement track of each cell relative to its starting position (origin). 
(a) No magnet, no nTMag. (b) Magnet, no nTMag. (c) No magnet, 3 µL nTMag. (d) Magnet, 3 µL 






Figure 6.7 Quantification of NSC tracking in the presence of a 38 kg-pull NdFeB magnet with 0 µL or 3 
µL nTMag. The data show a trend of increased distance, speed and directionality in the presence of 




Tukey post-hoc. (b) Mean euclidean distance for each experimental condition. p>0.05, ANOVA with 
Tukey post-hoc. (c) Mean velocity for each experimental condition. p>0.05, ANOVA with Tukey post-
hoc. (d) Mean x and y migration indices for each experimental condition. p>0.05, ANOVA with Tukey 
post-hoc. (e) Mean x and y centres of mass for each experimental condition. p>0.05, ANOVA with Tukey 














not	 significant	 (p>0.05),	 directionality	 in	 the	 x	 axis	 tended	 to	 increase	 in	 the	 presence	 of	 the	
electromagnet,	 as	 measured	 by	 forward	 migration	 indices	 and	 centres	 of	 mass.	 The	 y	 forward	
migration	 index	was	 significantly	 greater	 (p<0.05,	ANOVA	with	 Tukey	post-hoc)	 in	NSCs	with	 0	µL 





Figure 6.8 Cell tracking analysis of GFP-NSCs with a 25 kg-pull electromagnet using the plugin mTrack. 
Cell tracking demonstrates increased directionality in the presence of the magnet. (a) Images of tracked 
cells ± the electromagnet, with the starting and final frame shown for each condition. Scale bars: 50 
µm. (b) Cell movement plots for each condition, showing the movement tracks of every cells relative to 
its starting position (origin). (c) Mean accumulated distance, shown with the values for the tracking 
experiments with the 23 kg and 38 kg-pull NdFeB magnets with no nTMag for comparison. p>0.05, 




experiments with the 23 kg and 38 kg-pull NdFeB magnets with no nTMag for comparison. p>0.05, 
ANOVA with Tukey post-hoc. (e) Mean velocity, shown with the values for the tracking experiments 
with the 23 kg and 38 kg-pull NdFeB magnets with no nTMag for comparison. p>0.05, ANOVA with 
Tukey post-hoc. (f) Mean x and y migration indices, shown with the values for the tracking experiments 
with the 23 kg and 38 kg-pull NdFeB magnets with no nTMag for comparison. *p<0.05, ANOVA with 
Tukey post-hoc. *represents 0 µL with 38 kg-pull magnet vs. all other groups y forward migration index. 
(g) Mean x and y centres of mass, shown with the values for the tracking experiments with the 23 kg 
and 38 kg-pull NdFeB magnets with no nTMag for comparison. p>0.05, ANOVA with Tukey post-hoc. 
























Figure 6.9 (previous page) GFP-NSC migration into the mouse retinal explant with a permanent 38 
kg-pull magnet. (a) Experimental set-up. The magnet was placed directly underneath the culture dish 
and the NSCs were placed directly on top of the explant, as shown. (b) Locations for confocal images 
of explant following migration experiment. One area in each quadrant of the retina was imaged. (c) 
Representative images of the GCL after 3 hours of NSC migration in the absence (left) and presence 
(right) of the magnet. The orthogonal views are presented. Scale bars: 100 µm. (d) Orthogonal XZ view 
of control (top) and magnet (bottom) explants are shown in higher magnification to demonstrate 
increased depth of NSC migration in the IPL in the presence of the magnet. Scale bars: 10 µm. (e) 
Quantification of green channel intensity at different depths of the IPL with and without the magnet. 








cells	 in	 suspension	using	magnetic	 fields,	 rather	 than	 traditional	 cell	migration	 across	 a	 substrate.	
Without	 measuring	 the	 changes	 in	 activation	 levels	 of	 proteins,	 such	 as	 Rac	 (Ridley	 et	 al.	 1999),	
following	 introduction	of	a	magnetic	 field	the	NSC	movement	 in	the	retinal	explant	also	cannot	be	
confirmed	as	cell	migration.	Nevertheless,	the	results	thus	far	are	promising	for	the	use	of	magnetic	
fields	to	direct	stem	cells	for	the	efficient	delivery	of	neurotrophic	agents.	




would	 be	 interesting	 to	 segment	migration	 analysis	 into	 smaller	 bands	 and	 examine	 the	 effect	 of	
distance	 from	magnet	surface	–	especially	as	magnetic	 field	strength	declines	exponentially	as	 the	
inverse	 square	 of	 the	 distance.	 The	 lack	 of	 significance	 also	 reflects	 large	 variability	 in	movement	
patterns	 of	NSCs	 in	 suspension,	 particularly	 in	 vitro.	 Experiments	 should	 therefore	be	 repeated	 in	
order	to	obtain	data	for	a	much	greater	number	of	cells,	and	over	longer	time	periods.	
Temperature	 is	 likely	 to	 be	 a	 factor	 that	 was	 largely	 overlooked	 in	 the	 current	 study.	 In	 the	
experiments	described	here,	the	NSCs	were	taken	from	a	37°C	incubator	and	imaged	in	a	room	that	
was	 not	 temperature	 controlled.	 These	 will	 likely	 have	 resulted	 in	 the	 formation	 of	 convection	




























There	was	no	 significant	effect	of	external	magnetic	 fields	 (permanent	or	electromagnetic)	on	 the	
movement	of	NSCs	in	suspension	in	vitro,	even	following	inclusion	of	mnps.	In	contrast,	application	of	












There	 are	 a	 number	 of	 challenges	with	working	with	 this	model.	One	 problem	 is	 that	 there	 is	 no	
‘perfect’	RGC	marker.	Thy1	is	one	of	the	most	widely	used	RGC	markers,	but	only	labels	70%	of	RGCs	
(Perry	et	al.	1984)	and	 fluctuates	 in	expression	 level	 following	optic	nerve	damage	 (Schlamp	et	al.	
2001;	Astafurov	et	al.	2014).	 It	would	be	 interesting	to	compare	the	 levels	of	Thy1	to	the	 levels	of	
other	neuronal	markers,	such	as	Brn3,	NeuN	and	TUJ1	to	allow	a	more	accurate	assessment	of	the	
number	of	RGCs.	Given	that	there	is	no	perfect	marker	of	RGCs	and	viability	markers	are	not	reliable	
markers	 of	 cell	 death	 in	 this	model,	 nuclear	 staining	 likely	 provides	 the	best	 readout	 of	 RGC	 loss,	
particularly	given	that	amacrine	cells	are	resistant	to	cell	death	(Kunzevitzky	et	al.	2010)	and	so	their	













classification	 (distal	 dendrites	 and	 dendritic	 field	 size)	 are	 often	 altered.	 This	 problem	 can	 be	
circumvented	with	 the	 use	 of	 parameters	 that	 are	 resistant	 to	 change,	 such	 as	measurements	 of	
proximal	dendrites	(Tribble	et	al.	2014).	
Pan-caspase	inhibition	was	modestly	protective	against	retraction	of	proximal	dendrites	(Figure	3.8c	















oxygen	 species,	 or	 glutamate-induced	 excitotoxicity	 caused	 by	 increased	 glutamate	 secretion	 that	
have	 been	 shown	 to	 induce	 dendritic	 atrophy	 in	 CA1	 and	CA3	pyramidal	 neurons	 (Christian	 et	 al.	
2011).	These	mechanisms	may	have	played	a	role	in	the	dendritic	retraction	of	RGCs	measured	here.	
	Dendrite	loss	implies	synapse	loss.	Since	synapses	are	formed	throughout	dendritic	arbors	(Spruston	






synaptic	 markers	 VGlut1	 and	 synaptophysin	 (Johnson	 et	 al.	 2007;	 Ippolito	 and	 Eroglu	 2010).	
Alternatively,	biolistic	labelling	could	be	used	(Lo	et	al.	1994;	Morgan	et	al.	2008).	Biolistic	labelling	
would	be	preferable	since	it	would	permit	quantification	of	the	rate	of	synapse	loss	with	time-series	
imaging.	 Although	widespread	 dendrite	 loss	 is	 likely	 to	 be	 accompanied	 by	 synapse	 loss,	 the	 two	
events	may	not	occur	concurrently,	as	shown	in	a	mouse	model	of	Alzheimer’s	disease	where	dendrite	
loss	precedes	synapse	 loss	 (Williams	et	al.	2013b).	Biolistics	would	allow	the	 relationship	between	






























since	exogenous	BDNF	 is	difficult	 to	control	 in	vivo,	 the	ex	vivo	model	 is	a	more	reliable	platform.	
Further,	the	optic	nerve	crush	is	not	a	consistent	injury,	unlike	the	total	axotomy	performed	here.	In	
line	with	the	mechanism	of	BDNF	I	propose	here,	it	has	been	reported	in	the	mouse	retinal	explant	
that	 Thy1-YFP	 labelled	 RGCs	 show	 reduced	 dendrite	 loss	 with	 a	 combination	 of	 BDNF	 and	 CNTF	
(Johnson	et	al.	2016).	However,	the	true	therapeutic	effect	is	not	clear	since,	as	previously	outlined,	









ability	of	neuronal	networks	 to	compensate	 for	cell	 loss.	Here,	 I	 show	for	 the	 first	 time	that	BDNF	
treatment	 initiated	3	d-post	axotomy	offers	 significant	protection	against	dendritic	 retraction,	and	
may	 promote	 dendritic	 outgrowth.	 It	 will	 be	 important	 to	 determine	 how	 sustained	 the	
neuroprotective	effects	of	BDNF	are	in	this	model	prior	to	in	vivo	trials.	
The	morphometric	data	 from	retinal	explants	 treated	with	delayed	BDNF	 (Figure	4.3	 in	Chapter	4)	
presented	here	are	suggestive	of	a	neurite	outgrowth	mechanism	of	BDNF,	similar	to	that	reported	in	
the	 adult	 guinea	 pig	 auditory	 nerve	 (Miller	 et	 al.	 2007).	 However,	 it	 should	 be	 noted	 that	 this	
hypothesis	needs	to	be	confirmed	by	time-series	imaging.	Nevertheless,	the	prospect	of	an	agent	that	




This	 could	 be	 achieved	 by	 biolistic	 labelling,	 for	 example	 using	 PSD-95,	 which	 could	 be	 used	 in	
combination	 with	 biolistic	 labelling	 of	 cytoskeletal	 markers	 in	 order	 to	 validate	 the	 dendritic	
outgrowth	mechanism	of	BDNF.	
BDNF	is	an	attractive	candidate	for	treatment	of	retinal	degeneration	because	it	has	been	reported	









1999).	Confirmation	 that	p75NTR	 is	not	expressed	by	RGCs	 in	 the	explant	would	 support	 cell-based	
delivery	of	BDNF	because	presumably	any	secreted	pro-BDNF	would	not	have	a	negative	effect	on	
RGCs.	It	would	be	interesting	to	map	the	expression	levels	of	TrkB	and	p75NTR	over	time	in	the	retinal	













BDNF	 treatment.	 Over	 longer	 culture	 periods	 (6	 d)	 ChABC	 treatment	 promoted	 RGC	 dendritic	






















explain	 the	 inhibitory	 effect	 of	 ChABC	 treatment	 on	 BDNF-induced	 neuroprotection,	 even	 when	
ChABC	and	BDNF	were	not	present	at	the	same	time.		
The	possible	effect	of	NCAM	on	BDNF-TrkB	binding	 strengthens	 the	 case	 for	using	TrkB	activating	
agents	in	place	of	BDNF.	TrkB	agonists	improved	RGC	survival	in	models	of	optic	nerve	injury	(Hu	et	




























magnetic	 field-sensitive	 receptor	 has	more	 recently	 become	 generally	 accepted	 (Lohmann	 2016).	
There	is	evidence	that	a	magnetoreceptor	may	explain	the	migratory	behaviour	of	several	organisms,	
including	bacteria,	drosophila	and	homing	pigeons	(Mora	et	al.	2004;	Baumgartner	et	al.	2013;	Qin	et	
al.	 2016)	 but	 researchers	 have	 debated	 the	 existence	 of	 such	 a	 receptor	 in	 mammals,	 including	
humans.	The	data	I	present	here	supports	the	existence	of	a	mammalian	magnetoreceptor	and	poses	
the	exciting	possibility	of	using	external	magnetic	fields	to	control	both	the	migration	and	the	selective	
gene	 expression	 of	 stem	 cells	 to	 deliver	 neurotrophic	 support	 to	 degenerating	 neurons.	 Since	
activation	of	the	magnetoreceptor	stimulates	calcium	influx	(Knoepfel	and	Akemann	2010;	Long	et	al.	




























could	be	alleviated	by	 the	use	of	electromagnets	 in	MRI	 scanners,	which	 contain	 cooling	 systems.	
Large	 electromagnets	 such	 as	 these	 circumvent	 the	 need	 to	 implant	 magnets,	 and	 have	 been	










The	 adult	 mouse	 retinal	 explant	 is	 an	 excellent	 model	 for	 the	 investigation	 of	 axotomy-induced	
neuronal	degeneration,	applicable	to	a	wide	range	of	CNS	disorders.	Morphometric	analysis	permits	
quantification	of	neuronal	cell	health,	as	well	as	inferred	information	regarding	synaptic	connectivity	
and	 functional	 ability.	 I	 have	 demonstrated	 that	 morphometric	 data	 can	 highlight	 a	 therapeutic	
window	in	which	to	probe	mechanisms	implicated	in	neuronal	pathology	and	neuroprotection.		In	this	
model	it	has	been	shown	that	the	activation	of	TrkB	provides	potent	neuroprotection	to	RGC	dendritic	





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































xFMI cell = 	 xOPQaccumulated	distance	
	
xFMI mean = 	1n xFMI(cell)\]\^_ 	
 
Equation S1. X forward migration index 
	
	
yFMI cell = 	 yOPQaccumulated	distance	
	
yFMI mean = 	1n yFMI(cell)\]\^_ 	
	
Equation S2. Y forward migration index 
	
x	centre	of	mass = 	 1n endpoint	x	





y	centre	of	mass = 	 1n endpoint	y	
Equation S4. Y centre of mass 
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